Insight

Ilya Tsimafeyeu: Promising Results for the Bevacizumab plus Erlotinib in Hereditary and Sporadic Papillary Renal Cell Carcinoma

Ilya Tsimafeyeu/bucare.org

Jun 26, 2025, 08:50

Ilya Tsimafeyeu: Promising Results for the Bevacizumab plus Erlotinib in Hereditary and Sporadic Papillary Renal Cell Carcinoma

Ilya Tsimafeyeu, Director at the Bureau of Cancer Research, shared a post on Facebook:

“Long-term follow-up has shown promising results for the combination of bevacizumab and erlotinib in hereditary and sporadic papillary renal cell carcinoma.

I treated two patients with HLRCC-related kidney cancer, and both experienced durable partial responses to bev plus erlo.

Additionally, I prescribed this combination to a patient with metastatic FH-deficient papillary RCC, who achieved a complete response. I can strongly recommend!”

Title: Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer

Journal: NEJM

Authors: Ramaprasad Srinivasan, Sandeep Gurram, Eric A. Singer, Abhinav Sidana, Munjid Al Harthy, Mark W. Ball, Julia C. Friend, Lisa Mac, Erin Purcell, Cathy D. Vocke, Christopher J. Ricketts, Heidi H. Kong, Edward W. Cowen, Ashkan A. Malayeri, Joanna H. Shih, Maria J. Merino, W. Marston Linehan

Read the full article.

Bevacizumab

More posts featuring Ilya Tsimafeyeu on OncoDaily.

Bevacizumab cancer Erlotinib hereditary papillary renal cell carcinoma HLRCC-related kidney cancer Ilya Tsimafeyeu kidney cancer OncoDaily Oncology papillary renal cell carcinoma sporadic papillary renal cell carcinoma

Padraic O’Malley: Meet the Experts of VIRO 2025

Hidden Risks: BRCA Mutations and Breast Implants - CancerWorld

FDA Breakthrough Therapy Designation for Iza-bren: Advancing Treatment for EGFR-Mutant NSCLC

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Author?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen